Cel-Sci Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>CC</div>
CVM -- USA Stock  

USD 18.36  0.30  1.66%

It looks like DiaMedica Therapeutics will continue to recover much faster as its share price surged up 3.48% today to Cel Sci's 28.6082%. As many rational traders are trying to avoid healthcare space, it makes sense to summarize Cel Sci a little further and understand how it stands against DiaMedica Therapeutics and other similar entities. We are going to summarize some of the competitive aspects of both Cel Sci and DiaMedica.
Published over three weeks ago
View all stories for Cel-Sci Corp | View All Stories
Will DiaMedica (NASDAQ:DMAC) shadow Cel Sci price jump?
By analyzing existing basic indicators between Cel Sci and DiaMedica, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in DiaMedica with a short position in Cel Sci. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cel Sci has an asset utilization ratio of 4.82 percent. This denotes that the company is making $0.0482 for each dollar of assets. An increasing asset utilization means that Cel Sci is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Cel-Sci or Precision is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Cel-Sci Corp's Liquidity

Cel-Sci Corp financial leverage refers to using borrowed capital as a funding source to finance Cel-Sci Corp ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cel-Sci Corp financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Cel-Sci Corp's total debt and its cash.

Correlation Between Cel-Sci and Precision Biosciences

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Cel-Sci Corp together with similar or unrelated positions with a negative correlation. For example, you can also add Precision Biosciences to your portfolio. If Precision Biosciences is not perfectly correlated to Cel-Sci Corp it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Cel-Sci Corp for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Please check pair correlation details between CVM and DTIL for more information.

Another Deeper Perspective

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Lets now check Cel Sci revenue. Based on the latest financial disclosure, Cel Sci reported 558.66 K of revenue. This is 99.99% lower than that of the Healthcare sector and 99.92% lower than that of the Biotechnology industry. The revenue for all United States stocks is 99.99% higher than that of Cel Sci. As for DiaMedica Therapeutics we see revenue of 447.37 K, which is 99.94% lower than that of the Biotechnology

742.9 M
Sector742.91 Million99.86

Are Cel Sci technical ratios showing a correction?

New Information Ratio is up to 0.08. Price may pull down again. Cel Sci is displaying above-average volatility over the selected time horizon. Investors should scrutinize Cel Sci independently to ensure intended market timing strategies are aligned with expectations about Cel Sci volatility.

While other companies under the biotechnology industry are still a bit expensive, Cel Sci may offer a potential longer-term growth to stakeholders. To conclude, as of the 30th of January 2021, we see that Cel Sci hyperactively responds to market trends. The company is overvalued with high probability of distress within the next 24 months. Our latest 30 days buy-or-sell advice on the company is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Cel-Sci Corp. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com